PURPOSE: BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a continuous daily schedule to patients with advanced solid tumor(s). METHODS: This was a multi-institutional, open-label, Phase I, single-arm dose escalation study in which cohorts of eligible patients with advanced malignancies were treated with BMS-275183 orally on a continuous daily schedule. The starting dose level was 6 mg/m(2)/day administered once daily. Cohorts of 3 patients were treated at each dose level provided no dose-limiting toxicities (DLTs) were observed. Each cycle of treatment lasted 28 days. RESULTS: Twenty patients were enrolled in dose cohorts ranging from the initial dose level of 6 mg/m(2)/day to 18 mg/m(2)/day. Overall, the most frequent (>20% of patients) treatment-related adverse events (AEs) were nausea (40%), constipation (20%), diarrhea (20%), and fatigue (20%). There were 2 fatal events of neutropenic sepsis one each at the 15 mg/m(2)/day and 18 mg/m(2)/day dose level, respectively. There were no objective responses; 4 of 20 patients experienced stable disease. Pharmacokinetic data indicated no clear correlation between dose and exposure following daily oral administration of BMS-275183 doses between 6 and 18 mg/m(2). Substantial inter-patient variability was observed, and high drug exposure was associated with fatal neutropenic sepsis. CONCLUSIONS: BMS-275183 is a novel oral analogue of paclitaxel with high inter-patient variability in exposure. The lack of evidence of clinical benefit and the occurrence of two fatal events of neutropenic sepsis, coupled with high drug exposure, argues against further evaluation of BMS-275183 on a daily dosing schedule.
PURPOSE: BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a continuous daily schedule to patients with advanced solid tumor(s). METHODS: This was a multi-institutional, open-label, Phase I, single-arm dose escalation study in which cohorts of eligible patients with advanced malignancies were treated with BMS-275183 orally on a continuous daily schedule. The starting dose level was 6 mg/m(2)/day administered once daily. Cohorts of 3 patients were treated at each dose level provided no dose-limiting toxicities (DLTs) were observed. Each cycle of treatment lasted 28 days. RESULTS: Twenty patients were enrolled in dose cohorts ranging from the initial dose level of 6 mg/m(2)/day to 18 mg/m(2)/day. Overall, the most frequent (>20% of patients) treatment-related adverse events (AEs) were nausea (40%), constipation (20%), diarrhea (20%), and fatigue (20%). There were 2 fatal events of neutropenic sepsis one each at the 15 mg/m(2)/day and 18 mg/m(2)/day dose level, respectively. There were no objective responses; 4 of 20 patients experienced stable disease. Pharmacokinetic data indicated no clear correlation between dose and exposure following daily oral administration of BMS-275183 doses between 6 and 18 mg/m(2). Substantial inter-patient variability was observed, and high drug exposure was associated with fatal neutropenic sepsis. CONCLUSIONS: BMS-275183 is a novel oral analogue of paclitaxel with high inter-patient variability in exposure. The lack of evidence of clinical benefit and the occurrence of two fatal events of neutropenic sepsis, coupled with high drug exposure, argues against further evaluation of BMS-275183 on a daily dosing schedule.
Authors: M T Huizing; G Giaccone; L J van Warmerdam; H Rosing; P J Bakker; J B Vermorken; P E Postmus; N van Zandwijk; M G Koolen; W W ten Bokkel Huinink; W J van der Vijgh; F J Bierhorst; A Lai; O Dalesio; H M Pinedo; C H Veenhof; J H Beijnen Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Harold Mastalerz; Donald Cook; Craig R Fairchild; Steven Hansel; Walter Johnson; John F Kadow; Byron H Long; William C Rose; James Tarrant; Mu-Jen Wu; May Quifen Xue; Guifen Zhang; Mary Zoeckler; Dolatrai M Vyas Journal: Bioorg Med Chem Date: 2003-10-01 Impact factor: 3.641
Authors: Linda E Bröker; Filip Y F L de Vos; Cees J van Groeningen; Bart C Kuenen; Helen E Gall; Michael H Woo; Maurizio Voi; Jourik A Gietema; Elisabeth G E de Vries; Giuseppe Giaccone Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Linda E Bröker; Stephan A Veltkamp; Elisabeth I Heath; Bart C Kuenen; Helen Gall; Ludovic Astier; Susan Parker; Louis Kayitalire; Patricia M Lorusso; Jan H M Schellens; Giuseppe Giaccone Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Serena Marchetti; Dick Pluim; Jos H Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H M Schellens Journal: Invest New Drugs Date: 2014-07-31 Impact factor: 3.850
Authors: Neha N Parayath; Hayley Nehoff; Samuel E Norton; Andrew J Highton; Sebastien Taurin; Roslyn A Kemp; Khaled Greish Journal: Int J Nanomedicine Date: 2016-08-17